DXCM vs LUNG

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

DXCM

47.1
AI Score
VS
DXCM Wins

LUNG

32.6
AI Score

Investment Advisor Scores

DXCM

47score
Recommendation
HOLD

LUNG

33score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DXCM LUNG Winner
Revenue 3.84B 66.18M DXCM
Net Income 723.70M -32.13M DXCM
Gross Margin 63.6% 77.3% LUNG
Net Margin 18.8% -48.5% DXCM
Operating Income 900.80M -29.50M DXCM
ROE 28.5% -93.9% DXCM
ROA 11.6% -29.2% DXCM
Total Assets 6.24B 110.21M DXCM
Cash 961.40M 52.69M DXCM
Current Ratio 1.74 4.05 LUNG
Free Cash Flow 906.20M -18.51M DXCM

Relative Price Performance (Last 90 Days)

DXCM 1M: -7.0% · 3M: -12.0% LUNG 1M: +55.6% · 3M: +22.3%

Current Technical Phase

DXCM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 44

RSI (14): 44.1 · Price: $79.92

LUNG

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 62

RSI (14): 62.5 · Price: $2.80

Fundamentals Snapshot

Metric DXCM LUNG
Market Cap — —
Forward P/E 25.5 -3.1
Trailing P/E 31.9 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.6% 0.8%
Operating Margin 0.2% -0.3%
EPS 2.54 -1.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DXCM is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.